Prostaglandin analogues in the treatment of glaucoma

Drugs and Aging

Volumn 14, Issue 5, 1999, Pages 387-398

  Lindén, Christina ^a   Alm, Albert ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; LATANOPROST; MELANIN; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR; UNOPROSTONE ISOPROPYL ESTER;

CONJUNCTIVA DISEASE; CORNEA EROSION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPEREMIA; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MELANOCYTE; OPEN ANGLE GLAUCOMA; PIGMENT DISORDER; PRIORITY JOURNAL; REVIEW;

ANIMALS; DINOPROST; FORECASTING; GLAUCOMA; HUMANS; POLYPHARMACY; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC;

EID: 0032952624     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914050-00006     Document Type: Review

References (108)

1. Leske MC. The epidemiology of open angle glaucoma: A review. Am J Epidemiol 1983; 118: 166-91
2. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 199 1; 325: 1412-7
3. Tucker JB. Screening for open-angle glaucoma. Am Fam Physician 1993; 48: 75-80
4. Bill A. The aqueous humor drainage mechanism in the cynomolgus monkey (Maraca irus) with evidence for unconventional routes. Invest Ophthalmol 1965; 4: 911-9
5. 2α Arch Ophthalmol 1987; 105: 1112-6
6. 2α on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res 1987; 6: 1035-44
7. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989; 48: 707-16
8. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989; 49: 389-402
9. 2α on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res 1990; 51: 87-91
10. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100: 1297-304
11. 2α analogue. In: Samuelsson B, et al., editors. Advances in Prostaglandin, Thromboxane, and Leukotriene Research. New York; Raven Press, 1995: 513-8
12. Bito LZ, Salvador EV. Intraocular fluid dynamics: III. The site and mechanism of prostaglandin transfer across the blood intraocular fluid barriers. Exp Eye Res 1972; 14: 233-41
13. Ferreira SH, Vane JR. Prostaglandins: Their disappearance from and release into the circulation. Nature 1967; 216: 868-73
14. Rang HP, Dale MM, Ritter JM. Local hormones, inflammation and allergy. In: Pharmacology. 3rd Ed. New York: Churchill Livingstone, 1995: 214-45
15. Coleman RA, Smith WL, Narumiya S. International union of pharmacology classification of prostanoid receptors; properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46; 205-29
16. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci 1996; 37: 716-26
17. Kurzrok R, Lieb CC. Biochemical studies of human semen: II. The action of semen on the human uterus. Proc Soc Exp Biol Med 1930; 28: 268-72
18. Goldblatt MW. A depressor substance in seminal fluid. J Soc Chem Industry 1933; 5: 1056-7
19. Goldblatt MW. Properties of human seminal plasma. J Physiol (Lond) 1935; 84: 208-18
20. von Euler US. Zur Kenntnis der pharmakologischen Wirkungen von Nativsekreten und Extrakten männlicher accessorischer Geschlechtsdrüsen. Naunyn Schmeidesbergs Arch Exp Pathol Pharmakol 1934; 175: 78-84
21. Ambache N. Irin. a smooth-muscle contracting substance present in rabbit iris. J Physiol (Lond) 1955; 129: 65P-6
22. Ambache N. Properties of irin, a physiological constituent of the rabbit's iris. J Physiol (Lond) 1957; 135: 114-32
23. 2α prostaglandins and related factors 21. Biochem Pharmacol 1964; 13: 281-3
24. Ambache N, Kavanagh L, Whiting J. Some differences in uveal reactions between cats and rabbits. J Physiol (Lond) 1966; 182: 110-30
25. Ambache N, Brummer HC. A simple chemical procedure for distinguishing E from F prostaglandins, with application to tissue extracts. Br J Pharmacol 1968; 33: 162-70
26. 1 and aqueous humor dynamics. Invest Ophthalmol 1972; 11: 1022-7
27. Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci 1977; 16: 1125-34
28. 2α on aqueous humor dynamics of rabbit, cat and monkey. Invest Ophthalmol Vis Sci 1984; 25: 1087-93
29. Woodward DF, Williams LS, Chen J. Marked differential effects of prostanoid metabolites on rabbit intraocular pressure. Ophthalmic Res 1989; 21: 428-35
30. 2 lower intraocular pressure. Invest Ophthalmol Vis Sci 1985; 26: 1178-82
31. 2α. Curr Eye Res 1981; 1: 205-9
32. 2α on cat and rhesus monkey eyes. Invest Ophthalmol Vis Sci 1982; 22: 588-98
33. 2α or epinephrine on cynomolgus monkey eyes: II. slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest Ophthalmol Vis Sci 1987; 28: 921-6
34. 2α isopropyl ester versus Hoprost phenacyl ester in rabbit and beagle eyes. Curr Eye Res 1989; 8: 131-8
35. 2, and their esters in glaucomatous monkey eyes. Invest Ophthalmol Vis Sci 1990; 31: 2466-70
36. 2α isopropylesler on intraocular pressure in normotensive and glaucomatous canine eyes. J Ocul Pharmacol 1991; 7: 107-16
37. 2α in the human eye. Graefes Arch Clin Exp Ophthalmol 1985; 222: 139-41
38. 2α-1-isopropyl ester. Exp Eye Res 1987; 44: 217-26
39. 2α esters across cornea in vitro. Int J Pharm 1986; 29: 259-66
40. 2α. Br J Ophthalmol 1994; 78: 560-7
41. 2α-isoproylester eye drops: Effects in normal human eyes. Br J Ophthalmol 1989; 73: 419-26
42. 2α esters: A doublemasked cross-over study on normotensive eyes. Acta Ophthalmol 1990; 68: 341-3
43. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992; 17: 691-704
44. Sjöquist B, Almegård B, Khalifeh V. et al. The bioavailability of Xalatan® in the human eye [abstract]. Invest Ophthalmol Vis Sci 1997; 38: 248
45. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology 1995; 102: 1743-52
46. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138-47
47. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-mouth, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-37
48. 2α analogue: Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992; 76: 214-7
49. 2α-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993; 37: 259-69
50. Alm A, Villumsen J, Törnquist P, et al. Intraocular pressure. Reducing effect of PhXA41 in patients with increased eye pressure: A one-month study. Ophthalmology 1993; 100: 1312-7
51. Alm A, Villumsen J, PhXA34, a new potent ocular hypotensive drug: A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991; 109: 1564-8
52. Nagasubramanian S, Sheth GP, Hitchings RA, et al. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: Comparison of dose regimens. Ophthalmology 1993; 100: 1305-11
53. Alm A, Widengard I, Kjellgren D. et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995; 79: 12-6
54. Lindén C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Opthalmol 1997; 81: 370-2
55. Lindén C, Alm A. Latanoprost twice daily in less effective than once daily: Indication of receptor subsensitivity? Curr Eye Res 1998; 17: 567-72
56. 2α. Exp Eye Res 1988; 47: 761-9
57. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 1997; 38: 2214-23
58. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997; 38: 2272-80
59. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: A study on cultured cells and tissue sections. Exp Eye Res 1998; 67: 179-91
60. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111: 1351-8
61. Lindén C, Alm A. Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes. Acta Ophthalmol Scand 1997; 75: 412-5
62. 2α analogue (PhXA41): An in-hospital, placebo-controlled study. Arch Ophthalmol 1993; 111: 657-61
63. Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy: Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996; 103: 1916-24
64. Watson PG, the Latanoprost Study Group. Latanoprost: two years' experience of its use in the United Kingdom. Ophthalmology 1998; 105: 82-7
65. Mishima HK, Masuda K, Kitasawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: A 12-week study. Arch Ophthalmol 1996; 114: 929-32
66. Rácz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996; 114: 268-73
67. Stjernschantz J, Nilsson SFE, Astin M. Vasodynamic and angiogenic effects of eicsanoids in the eye. In: Bito LZ, Stjernschantz J, editors. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan R. Liss, Inc., 1989: 155-70
68. Nicolela MT, Buckley AR, Walman BE, et al. A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am J Ophthalmol 1996; 122: 784-9
69. 2α-isopropylester to timolol in patients with open angle glaucoma: a randomized, masked, placebo-controlled study. Arch Ophthalmol 1990; 108: 1102-5
70. 2α-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 1991; 98: 1079-82
71. 2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994; 78: 899-902
72. 2α/pilocarpine interactions on IOP and accommodation in monkeys. Exp Eye Res 1995; 54: 677-83
73. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993; 111: 662-5
74. Lindén C. Alm A. Physostigmine increases aqueous humor production in human eyes. Curr Eye Res 1997; 16: 1166-70
75. Lindén C, Alm A. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch Ophthalmol 1997; 115: 857-61
76. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 1997; 124: 279-86
77. Widengard I, Mäepea O, Alm A. Effects on latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol 1998; 82: 404-6
78. Rulo AH, Greve EL, Hoyng PFJ. Additive ocular hypotensive effect of latanoprost and acetazolamide: A short-term study in patients with elevated intraocular pressure. Ophthalmology 1997; 104: 1503-7
79. Azuara-Blanco A, Katz LJ, Spaeth GL, et al. Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment. Br J Ophthalmol 1997; 81: 1116
80. 2α functions as a local hormone on human airways. Respir Physiol 1980; 41: 183-97
81. 2α. Naunyn Schmeidesbergs Arch Pharmacol 1990; 341: 439-43
82. Hedner J, Svedmyr N, Lunde H, et al. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 1997; 41 Suppl. 2: S111-5
83. 2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol 1988; 105: 30-4
84. 2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 1989; 96: 1329-37
85. 2 receptor subtype. Invest Ophthalmol Vis Sci 1990; 31: 2463-6
86. 2α analogue. Surv Ophthalmol 1997; 41 Suppl. 2: S77-81
87. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997; 124: 683-5
88. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105: 263-8
89. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997; 41 Suppl. 2: S129-38
90. Stjernschantz J, Selén G, Ocklind A, et al. Prostaglandin-induced increase of iridial pigmentation [abstract]. Pigment Cell Res 1996; Suppl. 5: 19-20
91. Selén G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997; 41 Suppl. 2: S125-8
92. Prota G. Melanins and Melanogenesis. San Diego: Academic Press, 1992: 164-8
93. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997; 115: 1206-8
94. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-7
95. Goh Y, Kishino J. Pharmacological characterization of prostaglandin-related ocular hypotensive agents. Jpn J Ophthalmol 1994; 38: 236-45
96. Ueno R, Yoshida S, Deguchi T, et al. The intraocular pressure lowering effects of UF-021, a novel prostaglandin related compound, in animals [in Japanese]. Nippon Ganka Gakkai Zasshi 1992; 96: 462-8
97. Takase M, Murao M, Koyano S, et al. Ocular effects of topical instillation of UF-021 ophthalmic solution in healthy volunteers [in Japanese]. Nippon Ganka Gakkai Zasshi 1992; 96: 1261-7
98. Taniguchi T, Haque MSR, Sugiyama K, et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J Ocul Pharmacol Ther 1996; 12: 489-98
99. Sakurai M, Araie M, Oshika T, et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol 1991; 35: 156-65
100. Tetsuka H, Tsuchisaka H, Kin K, et al. A mechanism for reducing intraocular pressure in normal volunteers using UF-021, a prostaglandin-related compound [in Japanese]. Nippon Ganka Gakkai Zasshi 1992; 96: 496-500
101. Azuma I, Masuda K, Kitazawa Y, et al. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993; 37: 514-25
102. Yamamoto T, Kitazawa Y, Azuma I, et al. Clinical evaluation of UF-021 (Rescula®: isopropyl unoprostone). Surv Ophthalmol 1997; 41 Suppl. 2: S99-103
103. Serle JB, Podos SM, Kitazawa Y, et al. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 1998; 42: 95-100
104. Nakamatsu T, Okinami S, Oono S. The ocular hypotensive effect of concomitant use of isopropyl unoprostone (Rescula®) and timolol [in Japanese]. J Eye 1996; 13: 439-41
105. Kaburaki T, Ohashi M, Shirato S, et al. The additive effect of unoprostone ophthalmic solution for refractory glaucoma [in Japanese]. Jpn J Clin Ophthalmol 1997; 51: 1599-602
106. Aoyama Y, Ueno S. Effect of UF-021 (Rescula®), a prostaglandin-related compound, on intraocular pressure and anterior chamber flare counts [in Japanese]. Folia Ophthalmol Jpn 1996; 47: 914-9
107. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997; 6: 430-2
108. Pharmacia & Upjohn. Xalatan® Prescribing Information. Uppsala: Pharmacia & Upjohn, 1996